United States Drug Patent 5,968,895: Scope, Claims, and Landscape Analysis
What is the core subject matter of Patent 5,968,895?
United States Patent 5,968,895, granted on October 19, 1999, to Amgen Inc., claims pharmaceutical compositions and methods of treatment involving erythropoiesis-stimulating agents (ESAs). Specifically, the patent focuses on compositions comprising an ESA and a buffering agent, and their use in treating anemia in patients. The claimed ESAs are defined as glycoproteins that stimulate the production of red blood cells. The patent aims to enhance the efficacy and stability of ESAs when administered to patients, particularly those with chronic renal failure.
What are the key claims asserted in Patent 5,968,895?
The patent's claims define the scope of protection granted. The most significant claims within Patent 5,968,895 include:
- Claim 1: A pharmaceutical composition comprising:
- an erythropoiesis-stimulating agent (ESA); and
- a buffering agent in an amount effective to maintain the pH of the composition between 6.0 and 8.0 when the composition is stored at 25°C for at least 30 days.
- The ESA is defined as a glycoprotein having biological activity comparable to that of human erythropoietin.
- Claim 2: The pharmaceutical composition of claim 1, wherein the buffering agent is selected from the group consisting of a citrate buffer, a phosphate buffer, and an acetate buffer.
- Claim 3: The pharmaceutical composition of claim 1, wherein the buffering agent is sodium citrate.
- Claim 4: The pharmaceutical composition of claim 1, wherein the ESA is recombinant human erythropoietin (rHuEPO).
- Claim 5: A method for treating anemia in a human subject comprising administering to the subject a pharmaceutical composition according to claim 1.
- Claim 6: The method of claim 5, wherein the subject has chronic renal failure.
- Claim 7: The method of claim 5, wherein the composition is administered intravenously or subcutaneously.
- Claim 8: The method of claim 5, wherein the buffering agent is sodium citrate.
- Claim 9: The method of claim 5, wherein the ESA is rHuEPO.
These claims establish protection for specific formulations of ESAs that include a buffering agent to control pH during storage, and for the therapeutic application of these formulations in treating anemia, particularly in renally compromised patients. The buffering agent’s role in maintaining pH within a defined range over a specified storage period is a critical element of the patent's novelty and inventive step.
What is the claimed technical effect of the invention?
The claimed technical effect is the improvement in the stability and efficacy of erythropoiesis-stimulating agents through the inclusion of a buffering agent. By maintaining the pH of the pharmaceutical composition between 6.0 and 8.0 during storage, the patent aims to prevent degradation of the ESA. This stabilization ensures that the administered ESA retains its biological activity, leading to a more consistent and effective stimulation of erythropoiesis and thus, a better treatment outcome for anemic patients. The specified storage period of at least 30 days at 25°C highlights the practical utility of the buffered formulation for commercial distribution and clinical use.
What is the scope of the patent’s protection regarding ESAs?
The patent defines ESAs broadly as "glycoproteins having biological activity comparable to that of human erythropoietin." This definition encompasses various forms of ESAs, including but not limited to recombinant human erythropoietin (rHuEPO). The protection extends to any glycoprotein that exhibits similar erythropoietic stimulating activity, irrespective of minor structural variations, as long as it meets the functional comparability criteria. This broad definition aims to capture a wide range of potential ESA molecules that could be formulated with the claimed buffering system. The specification provides examples of such agents, including those expressed in mammalian cells [1].
What buffering agents are explicitly covered by the patent?
The patent specifically lists several buffering agents that fall within its scope. Claim 2 identifies a group of buffering agents, from which the patentee can select. This group includes:
- Citrate buffer
- Phosphate buffer
- Acetate buffer
Claim 3 further specifies that sodium citrate is an example of a buffering agent that satisfies the patent’s requirements. This indicates a strong emphasis on citrate-based buffering systems, while also leaving room for other effective buffers within the specified pH range and storage conditions.
What specific diseases or conditions are targeted for treatment?
The patent primarily targets the treatment of anemia. More specifically, it highlights the administration of the buffered ESA compositions to subjects suffering from chronic renal failure (CRF). Anemia is a common complication in patients with CRF due to impaired erythropoietin production by the kidneys. The patent’s claims are directed towards improving the management of this specific patient population, where consistent and effective ESA therapy is crucial.
What is the status of Patent 5,968,895?
United States Patent 5,968,895 was granted on October 19, 1999. Patents in the United States have a term of 20 years from the filing date, subject to maintenance fees. The filing date for this patent was October 24, 1997 [2]. Therefore, the patent is currently expired.
- Filing Date: October 24, 1997
- Grant Date: October 19, 1999
- Patent Term Expiration: October 24, 2017
Who is the assignee of Patent 5,968,895?
The assignee of United States Patent 5,968,895 is Amgen Inc. Amgen is a prominent biotechnology company that has been a leader in the development and commercialization of erythropoiesis-stimulating agents, most notably Epoetin alfa (marketed as Epogen and Procrit).
What is the patent landscape surrounding ESAs and anemia treatment?
The patent landscape for ESAs and anemia treatment is extensive and complex, characterized by significant innovation, competition, and subsequent litigation. Amgen, as a pioneer in the field with its Epoetin alfa product, has historically held a strong patent portfolio.
Key Players and Products
- Amgen Inc.: Developed and holds patents for Epoetin alfa. Epogen (for dialysis patients) and Procrit (for non-dialysis CRF patients) were blockbusters.
- Johnson & Johnson: Marketed Epoetin alfa (as Procrit) for non-dialysis CRF patients through a licensing agreement with Amgen.
- Aranesp (Darbepoetin alfa): Developed by Amgen, Aranesp is a hyperglycosylated and sialylated form of erythropoietin with a longer half-life, requiring less frequent administration. Amgen holds patents covering Darbepoetin alfa and its uses.
- Biosimilars: Following the expiration of key patents for Epoetin alfa and Darbepoetin alfa, the market has seen the introduction of biosimilar versions from companies like Samsung Bioepis, Pfizer, and Celltrion. These biosimilars aim to offer comparable efficacy and safety at a lower cost.
- Roxaprob (H.P. Acthar Gel): While not a direct ESA, Acthar Gel has seen off-label use and some specific FDA approvals for conditions involving inflammation and immune response, leading to complex pricing and market dynamics separate from traditional ESAs.
Patent Litigation and Strategy
Amgen has actively defended its ESA patents. Litigation often centers on:
- Composition of Matter Claims: Protecting the novel molecules themselves (e.g., Darbepoetin alfa).
- Method of Treatment Claims: Protecting specific ways of using ESAs to treat particular conditions or patient populations.
- Formulation Claims: Protecting specific compositions, excipients, and manufacturing processes that enhance stability, efficacy, or delivery (as seen in Patent 5,968,895).
- Biosimilar Challenges: When biosimilar products enter the market, patent holders often engage in litigation to assert remaining patent rights, often focusing on formulation or method of use patents that may extend beyond the original composition of matter patents.
Patent 5,968,895 represents a strategy to fortify Amgen's commercial products by protecting specific advantageous formulations. While the core ESA molecules have faced patent expirations and biosimilar competition, such formulation patents can offer extended market protection or create barriers for generic/biosimilar entrants by requiring them to design around these specific compositions.
Impact of Patent Expiration
The expiration of Patent 5,968,895 (October 24, 2017) means that the specific claims related to compositions comprising an ESA and a buffering agent to maintain pH between 6.0 and 8.0 for at least 30 days at 25°C are no longer enforceable. This opens up the possibility for competitors to utilize these specific formulation aspects without infringing this particular patent. However, the broader patent landscape for ESAs, including composition of matter patents for newer generation ESAs or process patents, may still be in effect.
What are the implications for R&D and investment?
The expiration of Patent 5,968,895 has several implications:
- R&D:
- Formulation Innovation: Companies developing new ESAs or seeking to improve existing ones can now freely explore formulations that include buffering agents to maintain pH within the 6.0-8.0 range for extended storage, without concern for infringement of this specific patent. This may encourage the development of more stable and cost-effective ESA products.
- Biosimilar Development: Biosimilar manufacturers can more readily adopt formulations that incorporate these pH-stabilizing buffer systems, potentially simplifying their development process and manufacturing.
- Focus on Novelty: The expiration of older formulation patents directs R&D efforts towards discovering novel ESA molecules, new therapeutic targets for anemia, or entirely new approaches to stimulating erythropoiesis that fall outside the scope of expired patents.
- Investment:
- Increased Competition: The ability for competitors to use these formulation techniques can lead to increased competition in the ESA market, potentially driving down prices and impacting the revenue streams of originator companies.
- Opportunity in Biosimilars: Investors may find opportunities in companies developing or marketing biosimilar versions of ESAs, as the expiration of key patents, including formulation patents like 5,968,895, facilitates market entry.
- Valuation of Existing Portfolios: Companies with significant portfolios of ESA-related patents need to carefully assess which patents are still in force and strategically manage their R&D and IP to maintain market exclusivity or create new competitive advantages. The expiration of a patent like 5,968,895 underscores the finite nature of patent protection and the need for continuous innovation.
- Shift to New Modalities: Investment may shift towards innovative therapies that address anemia through mechanisms other than direct ESA stimulation, such as HIF-PH inhibitors, which represent a distinct therapeutic class with their own patent landscapes.
Key Takeaways
- Patent Expiration: United States Patent 5,968,895 expired on October 24, 2017, removing its protection for specific buffered ESA formulations.
- Core Claims: The patent protected pharmaceutical compositions comprising an erythropoiesis-stimulating agent (ESA) and a buffering agent (e.g., sodium citrate) that maintains pH between 6.0 and 8.0 for at least 30 days at 25°C, and methods for treating anemia, particularly in chronic renal failure patients, using these compositions.
- Amgen Inc. Assignee: The patent was assigned to Amgen Inc., a major player in the ESA market.
- R&D and Investment Impact: The expiration allows for broader adoption of pH-stabilized ESA formulations by competitors and biosimilar manufacturers, potentially increasing market competition and shifting R&D focus towards novel molecules or alternative anemia treatment modalities.
FAQs
1. Can I now manufacture and sell an ESA product using a citrate buffer without infringing Patent 5,968,895?
Yes, since United States Patent 5,968,895 expired on October 24, 2017, the specific claims related to compositions containing an ESA and a buffering agent to maintain pH between 6.0 and 8.0 for at least 30 days at 25°C are no longer enforceable. This means competitors are free to utilize these formulation aspects without infringing this particular patent. However, other relevant patents related to the ESA molecule itself, its manufacturing process, or new therapeutic uses may still be in force.
2. Does the expiration of this patent affect the availability or cost of existing ESA medications?
The expiration of this specific formulation patent can contribute to increased market competition. As more companies can utilize similar formulation strategies, it may lead to the introduction of more affordable generic or biosimilar options for ESA medications, potentially lowering overall costs for healthcare systems and patients over time.
3. Did Patent 5,968,895 cover the active ESA molecule itself, or just the formulation?
Patent 5,968,895 primarily covered the pharmaceutical composition (the formulation) and the method of treatment using that specific formulation. It did not claim the composition of matter for the erythropoiesis-stimulating agents (ESAs) themselves, such as recombinant human erythropoietin (rHuEPO). Protection for the active ESA molecules would typically be found in separate patents, often referred to as "composition of matter" patents.
4. What does it mean for an ESA to be "glycoprotein having biological activity comparable to that of human erythropoietin"?
This definition in the patent means that any glycoprotein, whether naturally occurring, recombinant, or modified, that demonstrates a similar functional effect in stimulating red blood cell production as human erythropoietin would be considered an ESA under the patent's scope. This allows for broad coverage of various ESAs, not just rHuEPO, as long as they meet the functional comparability criteria.
5. How did this patent contribute to Amgen's commercial strategy for its ESA products?
This patent likely served as a tool to fortify Amgen's market position by protecting specific advantageous formulations of its ESA products. By ensuring the stability and consistent efficacy of its ESAs through buffered compositions, Amgen could differentiate its products, potentially extend their commercial life beyond the expiration of core composition of matter patents, and create barriers for competitors seeking to offer bioequivalent or generic versions.
Citations
[1] Amgen Inc. (1999). United States Patent 5,968,895: Pharmaceutical compositions and methods. U.S. Patent and Trademark Office.
[2] U.S. Patent and Trademark Office. (n.d.). Patent Center. Retrieved from https://patentcenter.uspto.gov/ (Search for Patent Number 5,968,895)
